|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Ottawa Hospital Research Institute The Kidney Foundation of Canada |
|---|---|
| Information provided by: | Ottawa Hospital Research Institute |
| ClinicalTrials.gov Identifier: | NCT00368147 |
Purpose
The purpose of this study is to determine if the creation of a fistula or a graft plays a role in the development of heart disease for patients undergoing hemodialysis
| Condition |
|---|
|
Arteriovenous Fistula Arteriovenous Graft Left Ventricular Hypertrophy Brain Natriuretic Peptide |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | Access Creation for Hemodialysis: Potential Contribution to Left Ventricular Remodelling |
| Enrollment: | 84 |
| Study Start Date: | April 2002 |
| Study Completion Date: | February 2007 |
Patients with end stage renal disease are at 18-20 times greater risk of dying from cardiovascular disease as the general population. Both traditional and non-traditional cardiovascular risk factors are thought to be important.
Of the non-tradtional cardiovascular risk factors, creation of an arteriovenous fistula or graft for the purposes of a blood access for hemodialysis may contribute to an elevation in BNP and left ventricular hypertrophy - both factors that have been associated with an increased risk of mortality Prior to access creation and at one month and one year post access creation - samples for BNP will be collected Prior to access creation and at one year post access creation - echocardiography will be performed
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: 1)Hemodialysis 2)high risk for heart failure (DM, age>50, and/or systolic dysfunction) 3) first arteriovenous fistula/graft 4) informed consent 5) technically adequate echocardiogram 6) stable hgb(>100) 7) stable mineral metabolism (normal calcium, phosphate <2.1mmol/L, PTH>50pmol/L)
Exclusion Criteria: 1)Expected survival <1 year 2) Expected to get a living donor transplant in one year 3)primary access failure 4) ARF
Contacts and Locations| Canada, Ontario | |
| University Heatlh Network | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Principal Investigator: | Deborah Zimmerman, MD | Ottawa Hospital Research Institute |
More Information
| Responsible Party: | Kidney Research Centre ( Deborah Zimmerman ) |
| Study ID Numbers: | 2002027-01H |
| Study First Received: | August 23, 2006 |
| Last Updated: | February 19, 2009 |
| ClinicalTrials.gov Identifier: | NCT00368147 History of Changes |
| Health Authority: | Canada: Health Canada |
|
Hemodialysis Arteriovenous Fistula Arteriovenous Graft Left Ventricular Hypertrophy Brain Natriuretic Peptide |
|
Pathological Conditions, Anatomical Natriuretic Peptide, Brain Hypertrophy, Left Ventricular Heart Diseases Cardiovascular Abnormalities Arteriovenous Fistula Vascular Diseases |
Fistula Hypertrophy Vascular Malformations Arteriovenous Malformations Congenital Abnormalities Cardiomegaly |
|
Pathological Conditions, Anatomical Hypertrophy, Left Ventricular Heart Diseases Cardiovascular Abnormalities Arteriovenous Fistula Vascular Fistula Vascular Diseases |
Fistula Hypertrophy Vascular Malformations Arteriovenous Malformations Cardiovascular Diseases Congenital Abnormalities Cardiomegaly |
